IL162507A - Use of ifnar2 mutants in the manufacture of medicaments - Google Patents

Use of ifnar2 mutants in the manufacture of medicaments

Info

Publication number
IL162507A
IL162507A IL162507A IL16250704A IL162507A IL 162507 A IL162507 A IL 162507A IL 162507 A IL162507 A IL 162507A IL 16250704 A IL16250704 A IL 16250704A IL 162507 A IL162507 A IL 162507A
Authority
IL
Israel
Prior art keywords
medicaments
manufacture
ifnar2
mutants
ifnar2 mutants
Prior art date
Application number
IL162507A
Inventor
Gideon Schreiber
Original Assignee
Yeda Res & Dev
Gideon Schreiber
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Res & Dev, Gideon Schreiber filed Critical Yeda Res & Dev
Priority to IL162507A priority Critical patent/IL162507A/en
Publication of IL162507A publication Critical patent/IL162507A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7156—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Cell Biology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Biotechnology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
IL162507A 2001-12-31 2004-06-14 Use of ifnar2 mutants in the manufacture of medicaments IL162507A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
IL162507A IL162507A (en) 2001-12-31 2004-06-14 Use of ifnar2 mutants in the manufacture of medicaments

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IL14741401A IL147414A0 (en) 2001-12-31 2001-12-31 Ifnar2 mutants, their production and use
PCT/IL2002/001059 WO2003059950A1 (en) 2001-12-31 2002-12-31 Ifnar2 mutants, their production and use
IL162507A IL162507A (en) 2001-12-31 2004-06-14 Use of ifnar2 mutants in the manufacture of medicaments

Publications (1)

Publication Number Publication Date
IL162507A true IL162507A (en) 2011-01-31

Family

ID=11075916

Family Applications (2)

Application Number Title Priority Date Filing Date
IL14741401A IL147414A0 (en) 2001-12-31 2001-12-31 Ifnar2 mutants, their production and use
IL162507A IL162507A (en) 2001-12-31 2004-06-14 Use of ifnar2 mutants in the manufacture of medicaments

Family Applications Before (1)

Application Number Title Priority Date Filing Date
IL14741401A IL147414A0 (en) 2001-12-31 2001-12-31 Ifnar2 mutants, their production and use

Country Status (16)

Country Link
US (2) US7749735B2 (en)
EP (2) EP2174955B1 (en)
JP (2) JP2005527195A (en)
KR (1) KR100891918B1 (en)
CN (1) CN100506845C (en)
BR (1) BR0215414A (en)
CA (1) CA2470245C (en)
EA (1) EA009604B1 (en)
HK (1) HK1072948A1 (en)
IL (2) IL147414A0 (en)
MX (1) MXPA04006383A (en)
NO (1) NO333821B1 (en)
NZ (1) NZ533539A (en)
UA (1) UA87958C2 (en)
WO (1) WO2003059950A1 (en)
ZA (1) ZA200404731B (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101293363B1 (en) * 2011-02-28 2013-08-05 성균관대학교산학협력단 A Composition for Preventing Bird Flu Comprising Interferon Receptor gene
CN103952413B (en) * 2014-05-14 2016-08-17 广东省农业科学院动物卫生研究所 The rnai expression vector construction of targeting IFNAR 2 gene and application
CN104762325B (en) * 2015-03-30 2018-04-17 山东省农业科学院家禽研究所 A kind of method of IFNAR2 genes in 1 cell lines of silence DF
CN105396123A (en) * 2015-11-20 2016-03-16 深圳市南山区人民医院 Application of ovR2E in curative effect of HBV infection treatment
WO2019040674A1 (en) 2017-08-22 2019-02-28 Sanabio, Llc Soluble interferon receptors and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4588585A (en) 1982-10-19 1986-05-13 Cetus Corporation Human recombinant cysteine depleted interferon-β muteins
US4737462A (en) 1982-10-19 1988-04-12 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
US4959314A (en) 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
US5116943A (en) 1985-01-18 1992-05-26 Cetus Corporation Oxidation-resistant muteins of Il-2 and other protein
ES2131513T3 (en) 1985-10-14 1999-08-01 Yeda Res & Dev USE OF HUMAN INTERFERON-BETA 2A FOR THE PREPARATION OF MEDICINES.
US5017691A (en) 1986-07-03 1991-05-21 Schering Corporation Mammalian interleukin-4
US4965195A (en) 1987-10-26 1990-10-23 Immunex Corp. Interleukin-7
US4904584A (en) 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
IL107378A (en) * 1993-10-24 2005-05-17 Yeda Res & Dev SOLUBLE INTERFERON alpha-RECEPTOR, ITS PREPARATION AND USE
US6193972B1 (en) * 1996-02-20 2001-02-27 Applied Research Systems Ars Holding N.V. Hybrid heterodimeric protein hormone
DE69805844T2 (en) 1997-12-19 2002-10-24 Applied Research Systems IFNNAR / IFN COMPLEX
IL126562A0 (en) 1998-10-14 1999-08-17 Interpharm Lab Ltd Expression and secretion of icil-1 receptor antagonist type ii
AUPP670698A0 (en) * 1998-10-23 1998-11-19 Monash University A method of regulation

Also Published As

Publication number Publication date
CA2470245A1 (en) 2003-07-24
AU2002366976A1 (en) 2003-07-30
KR100891918B1 (en) 2009-04-08
EP2174955B1 (en) 2014-04-16
US20100239530A1 (en) 2010-09-23
NO333821B1 (en) 2013-09-23
US7749735B2 (en) 2010-07-06
NO20042768L (en) 2004-09-22
HK1072948A1 (en) 2005-09-16
CN1622957A (en) 2005-06-01
EA009604B1 (en) 2008-02-28
JP2009165483A (en) 2009-07-30
KR20040086255A (en) 2004-10-08
IL147414A0 (en) 2002-08-14
WO2003059950A1 (en) 2003-07-24
US20050164185A1 (en) 2005-07-28
CA2470245C (en) 2012-03-27
JP2005527195A (en) 2005-09-15
MXPA04006383A (en) 2004-10-04
BR0215414A (en) 2004-12-14
NZ533539A (en) 2008-05-30
ZA200404731B (en) 2005-08-31
EA200400894A1 (en) 2004-12-30
UA87958C2 (en) 2009-09-10
EP2174955A1 (en) 2010-04-14
EP1461358A1 (en) 2004-09-29
CN100506845C (en) 2009-07-01

Similar Documents

Publication Publication Date Title
IL219671A0 (en) 1,2- benzoxazoles and use thereof in the preparation of a medicament
EP1367060A4 (en) Glucopyranosyloxybenzylbenzene derivatives and medicinal use thereof
EP1364957A4 (en) Glycopyranosyloxypyrazole derivatives and medicinal use thereof
EP1364958A4 (en) Glycopyranosyloxypyrazole derivatives and medicinal use thereof
PT1757606E (en) Xanthinderivatives for use as medical agents and the preparation thereof
AU2001256184A1 (en) 6-aminoalkyl-dihydropyrimidines and the use thereof as medicaments against viraldiseases
IL187528A0 (en) Use of pyrimidine compounds in the manufacture of medicaments
HK1068555A1 (en) New formulations and use thereof
PL387118A1 (en) Inhalation capsules comprising tiotropium and the use thereof
IL164463A (en) Use of osteoprotegerin in the preparation of medicaments
IL160780A0 (en) USE OF hCG IN THE MANUFACTURE OF A MEDICAMENT
IL159872A0 (en) Gmg-2 polypeptides and their use
HK1072948A1 (en) Ifnar2 mutants, their production and use
IL160875A0 (en) The use of botulinus toxin for the manufacture of a medicament and a cosmetic
EP1379228A4 (en) (z)-styrylbenzylsulfones and pharmaceutical uses thereof
HUP0400262A3 (en) Glycopeptides, their preparation and use in the treatment of multiple sclerosis
IL160782A0 (en) USE OF hCG IN THE MANUFACTURE OF A MEDICAMENT
IL160781A0 (en) Use of lh in the manufacture of a medicament
GB0119025D0 (en) Compounds and their therapeutic use
GB0124071D0 (en) Improvement in the administration of high boiling point aneasthetics
EP1367123A4 (en) Neurotonin and use thereof
IL163683A0 (en) Substituted 3-phenyl-5-alkoxy-1,3,4,-oxadiazol-2-ones, their preparation and use in medicaments
AU2002318186A1 (en) Novel human kielin-like proteins and polynucleotides encoding the same
IL146655A0 (en) The use of leptin in fertility
GB2376943B (en) Compounds and their therapeutic use

Legal Events

Date Code Title Description
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees